AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:13 2026-02-13 am EST			5-day change	1st Jan Change
15,118.00 ^GBX	+1.42%		+7.19%	+9.63%

Feb. 13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Feb. 13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT

UK Stocks-Factors to watch on January 12

Published on 01/12/2026 at 12:40 am EST - Modified on 01/12/2026 at 02:58 am EST

Reuters

Latest news about AstraZeneca PLC

Feb. 13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Feb. 13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT
Feb. 13	European Equities Mixed in Friday Trading; Spain's January CPI Declines	MT
Feb. 13	AstraZeneca Announces Positive and clinically meaningful Results from the Phase III KALOS and Logos Trials for Breztri in Patients with Undundant Ast Astrazeneca's Breztri in Patients	CI
Feb. 13	Shore Capital Downgrades AstraZeneca to Hold Rating	MT
Feb. 13	Stocks edge lower ahead of US CPI data	AN
Feb. 13	Stockholm Stock Exchange Declines on Friday After Intense Earnings Week	FW
Feb. 13	ASTRAZENECA : Bernstein maintains a Buy rating	ZD
Feb. 13	Bernstein, Barclays and Deutsche lower Relx	AN
Feb. 13	China Medical University Hospital Collaborates with Ever Supreme Bio Technology to Develop Exosome Platform	CI
Feb. 13	AstraZeneca rises on positive trial results for asthma therapy	AN
Feb. 13	AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials	MT
Feb. 13	NatWest results ahead of forecasts, ups dividend 51%	AN
Feb. 13	Swedish Stocks in North America - Ericsson Up 0.9 Percent	FW
Feb. 12	AbbVie sues US health agency over Botox price controls	RE

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

Mar. 02 - Daiwa Tokyo Investment Conference

More about the company